In vivo, the treatment with liraglutide blocked the upregulation of glomerular TLR4/MYD88/NF-κB signaling pathways, decreased proinflammatory cytokines and fibrosis-related indicators in the DN mouse model, and achieved regression of glomerular fibrosis. The gene discussed is MYD88; the disease is liver dysplastic nodule.